Brilliant Violet 421™ anti-human CD62L

Antibodies Single
Sony
DREG-56
Flow Cytometry
Mouse IgG1, κ
Human
2124135
$185.00

Description

CD62L is a 74-95 kD single chain type I glycoprotein referred to as L-selectin or LECAM-1. It is expressed on most peripheral blood B cells, subsets of T and NK cells, monocytes, granulocytes, and certain hematopoietic malignant cells. CD62L binds to carbohydrates present on certain glycoforms of CD34, glycam-1, and MAdCAM-1 and with a low affinity to anionic oligosaccharide sequences related to sialylated Lewis X (sLex, CD15s) through its C-type lectin domain. CD62L is important for the homing of naïve lymphocytes to high endothelial venules in peripheral lymph nodes and Peyer's patches. It also plays a role in leukocyte rolling on activated endothelial cells.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Kishimoto TK, et al. 1990. Proc. Natl. Acad. Sci. USA 87:2244. (WB, Block)
3. Jutila M, et al. 2002. J. Immunol. 169:1768. (WB)
4. Tamassia N, et al. 2008. J. Immunol. 181:6563. (FC) PubMed
5. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
6. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
7. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
9. Koenig JM, et al. 1996. Pediatr. Res. 39:616. (WB)
10. Shi C, et al. 2011. J. Immunol. 187:5293. (FC) PubMed
11. Burges M, et al. 2013. Clin Cancer Res. 19:5675. PubMed
12. Cash JL, et al. 2013. EMBO Rep. 14:999. (FC) PubMed